Global Bioburden Testing Industry

Global Bioburden Testing Market to Reach US$662. 4 Million by the Year 2027. Amid the COVID-19 crisis, the global market for Bioburden Testing estimated at US$377. 6 Million in the year 2020, is projected to reach a revised size of US$662.

New York, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Bioburden Testing Industry" - https://www.reportlinker.com/p05956102/?utm_source=GNW
4 Million by 2027, growing at a CAGR of 8.4% over the period 2020-2027.Instrument, one of the segments analyzed in the report, is projected to grow at a 8.2% CAGR to reach US$280.6 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Consumables segment is readjusted to a revised 8.5% CAGR for the next 7-year period. This segment currently accounts for a 57.3% share of the global Bioburden Testing market.

The U.S. Accounts for Over 29.6% of Global Market Size in 2020, While China is Forecast to Grow at a 7.9% CAGR for the Period of 2020-2027

The Bioburden Testing market in the U.S. is estimated at US$111.7 Million in the year 2020. The country currently accounts for a 29.59% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$115.4 Million in the year 2027 trailing a CAGR of 7.8% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.8% and 6.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.8% CAGR while Rest of European market (as defined in the study) will reach US$115.4 Million by the year 2027.We bring years of research experience to this 5th edition of our report. The 272-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

• ATS Laboratories, Inc.

• Becton, Dickinson and Company

• Charles River Laboratories International, Inc.

• Merck & Co., Inc.

• North American Science Associates, Inc.

• Pacific Biolabs

• SGS Group (SGS SA)

• Sigma-Aldrich Corporation

Read the full report: https://www.reportlinker.com/p05956102/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
Global Competitor Market Shares
Bioburden Testing Competitor Market Share Scenario Worldwide:
(in %): 2018E

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Bioburden Testing
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027

Table 2: World Historic Review for Bioburden Testing by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2017

Table 3: World 15-Year Perspective for Bioburden Testing by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2018 & 2027

Table 4: World Current & Future Analysis for Instrument by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027

Table 5: World Historic Review for Instrument by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2017

Table 6: World 15-Year Perspective for Instrument by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2018 & 2027

Table 7: World Current & Future Analysis for Consumables by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027

Table 8: World Historic Review for Consumables by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2017

Table 9: World 15-Year Perspective for Consumables by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2018 & 2027

Table 10: World Current & Future Analysis for Aerobic by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027

Table 11: World Historic Review for Aerobic by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2017

Table 12: World 15-Year Perspective for Aerobic by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2018 & 2027

Table 13: World Current & Future Analysis for Anaerobic by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027

Table 14: World Historic Review for Anaerobic by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2017

Table 15: World 15-Year Perspective for Anaerobic by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2018 & 2027

Table 16: World Current & Future Analysis for Fungi by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027

Table 17: World Historic Review for Fungi by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017

Table 18: World 15-Year Perspective for Fungi by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2018 & 2027

Table 19: World Current & Future Analysis for Spore by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027

Table 20: World Historic Review for Spore by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017

Table 21: World 15-Year Perspective for Spore by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2018 & 2027

Table 22: World Current & Future Analysis for Raw Material by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027

Table 23: World Historic Review for Raw Material by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2017

Table 24: World 15-Year Perspective for Raw Material by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2018 & 2027

Table 25: World Current & Future Analysis for In-process by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027

Table 26: World Historic Review for In-process by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2017

Table 27: World 15-Year Perspective for In-process by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2018 & 2027

Table 28: World Current & Future Analysis for Pharmaceutical &
Biotechnology Companies by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2018 through 2027

Table 29: World Historic Review for Pharmaceutical &
Biotechnology Companies by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017

Table 30: World 15-Year Perspective for Pharmaceutical &
Biotechnology Companies by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2012, 2018 & 2027

Table 31: World Current & Future Analysis for Contract
Manufacturing Organizations by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2018 through 2027

Table 32: World Historic Review for Contract Manufacturing
Organizations by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 33: World 15-Year Perspective for Contract Manufacturing
Organizations by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2018 & 2027

Table 34: World Current & Future Analysis for Microbial Testing
Laboratories by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2027

Table 35: World Historic Review for Microbial Testing
Laboratories by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 36: World 15-Year Perspective for Microbial Testing
Laboratories by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2018 & 2027

Table 37: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027

Table 38: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2017

Table 39: World 15-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2018 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
Market Facts & Figures
US Bioburden Testing Market Share (in %) by Company: 2018 & 2027
Market Analytics
Table 40: USA Current & Future Analysis for Bioburden Testing
by Product - Instrument and Consumables - Independent Analysis
of Annual Sales in US$ Million for the Years 2018 through 2027

Table 41: USA Historic Review for Bioburden Testing by Product -
Instrument and Consumables Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017

Table 42: USA 15-Year Perspective for Bioburden Testing by
Product - Percentage Breakdown of Value Sales for Instrument
and Consumables for the Years 2012, 2018 & 2027

Table 43: USA Current & Future Analysis for Bioburden Testing
by Type - Aerobic, Anaerobic, Fungi and Spore - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 44: USA Historic Review for Bioburden Testing by Type -
Aerobic, Anaerobic, Fungi and Spore Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 45: USA 15-Year Perspective for Bioburden Testing by Type -
Percentage Breakdown of Value Sales for Aerobic, Anaerobic,
Fungi and Spore for the Years 2012, 2018 & 2027

Table 46: USA Current & Future Analysis for Bioburden Testing
by Application - Raw Material and In-process - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 47: USA Historic Review for Bioburden Testing by
Application - Raw Material and In-process Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 48: USA 15-Year Perspective for Bioburden Testing by
Application - Percentage Breakdown of Value Sales for Raw
Material and In-process for the Years 2012, 2018 & 2027

Table 49: USA Current & Future Analysis for Bioburden Testing
by End-Use - Pharmaceutical & Biotechnology Companies, Contract
Manufacturing Organizations, Microbial Testing Laboratories and
Other End-Uses - Independent Analysis of Annual Sales in US$
Million for the Years 2018 through 2027

Table 50: USA Historic Review for Bioburden Testing by End-Use -
Pharmaceutical & Biotechnology Companies, Contract
Manufacturing Organizations, Microbial Testing Laboratories and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2017

Table 51: USA 15-Year Perspective for Bioburden Testing by
End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, Contract
Manufacturing Organizations, Microbial Testing Laboratories and
Other End-Uses for the Years 2012, 2018 & 2027

CANADA
Table 52: Canada Current & Future Analysis for Bioburden
Testing by Product - Instrument and Consumables - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 53: Canada Historic Review for Bioburden Testing by
Product - Instrument and Consumables Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 54: Canada 15-Year Perspective for Bioburden Testing by
Product - Percentage Breakdown of Value Sales for Instrument
and Consumables for the Years 2012, 2018 & 2027

Table 55: Canada Current & Future Analysis for Bioburden
Testing by Type - Aerobic, Anaerobic, Fungi and Spore -
Independent Analysis of Annual Sales in US$ Million for the
Years 2018 through 2027

Table 56: Canada Historic Review for Bioburden Testing by Type -
Aerobic, Anaerobic, Fungi and Spore Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 57: Canada 15-Year Perspective for Bioburden Testing by
Type - Percentage Breakdown of Value Sales for Aerobic,
Anaerobic, Fungi and Spore for the Years 2012, 2018 & 2027

Table 58: Canada Current & Future Analysis for Bioburden
Testing by Application - Raw Material and In-process -
Independent Analysis of Annual Sales in US$ Million for the
Years 2018 through 2027

Table 59: Canada Historic Review for Bioburden Testing by
Application - Raw Material and In-process Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 60: Canada 15-Year Perspective for Bioburden Testing by
Application - Percentage Breakdown of Value Sales for Raw
Material and In-process for the Years 2012, 2018 & 2027

Table 61: Canada Current & Future Analysis for Bioburden
Testing by End-Use - Pharmaceutical & Biotechnology Companies,
Contract Manufacturing Organizations, Microbial Testing
Laboratories and Other End-Uses - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027

Table 62: Canada Historic Review for Bioburden Testing by
End-Use - Pharmaceutical & Biotechnology Companies, Contract
Manufacturing Organizations, Microbial Testing Laboratories and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2017

Table 63: Canada 15-Year Perspective for Bioburden Testing by
End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, Contract
Manufacturing Organizations, Microbial Testing Laboratories and
Other End-Uses for the Years 2012, 2018 & 2027

JAPAN
Table 64: Japan Current & Future Analysis for Bioburden Testing
by Product - Instrument and Consumables - Independent Analysis
of Annual Sales in US$ Million for the Years 2018 through 2027

Table 65: Japan Historic Review for Bioburden Testing by
Product - Instrument and Consumables Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 66: Japan 15-Year Perspective for Bioburden Testing by
Product - Percentage Breakdown of Value Sales for Instrument
and Consumables for the Years 2012, 2018 & 2027

Table 67: Japan Current & Future Analysis for Bioburden Testing
by Type - Aerobic, Anaerobic, Fungi and Spore - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 68: Japan Historic Review for Bioburden Testing by Type -
Aerobic, Anaerobic, Fungi and Spore Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 69: Japan 15-Year Perspective for Bioburden Testing by
Type - Percentage Breakdown of Value Sales for Aerobic,
Anaerobic, Fungi and Spore for the Years 2012, 2018 & 2027

Table 70: Japan Current & Future Analysis for Bioburden Testing
by Application - Raw Material and In-process - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 71: Japan Historic Review for Bioburden Testing by
Application - Raw Material and In-process Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 72: Japan 15-Year Perspective for Bioburden Testing by
Application - Percentage Breakdown of Value Sales for Raw
Material and In-process for the Years 2012, 2018 & 2027

Table 73: Japan Current & Future Analysis for Bioburden Testing
by End-Use - Pharmaceutical & Biotechnology Companies, Contract
Manufacturing Organizations, Microbial Testing Laboratories and
Other End-Uses - Independent Analysis of Annual Sales in US$
Million for the Years 2018 through 2027

Table 74: Japan Historic Review for Bioburden Testing by
End-Use - Pharmaceutical & Biotechnology Companies, Contract
Manufacturing Organizations, Microbial Testing Laboratories and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2017

Table 75: Japan 15-Year Perspective for Bioburden Testing by
End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, Contract
Manufacturing Organizations, Microbial Testing Laboratories and
Other End-Uses for the Years 2012, 2018 & 2027

CHINA
Table 76: China Current & Future Analysis for Bioburden Testing
by Product - Instrument and Consumables - Independent Analysis
of Annual Sales in US$ Million for the Years 2018 through 2027

Table 77: China Historic Review for Bioburden Testing by
Product - Instrument and Consumables Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 78: China 15-Year Perspective for Bioburden Testing by
Product - Percentage Breakdown of Value Sales for Instrument
and Consumables for the Years 2012, 2018 & 2027

Table 79: China Current & Future Analysis for Bioburden Testing
by Type - Aerobic, Anaerobic, Fungi and Spore - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 80: China Historic Review for Bioburden Testing by Type -
Aerobic, Anaerobic, Fungi and Spore Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 81: China 15-Year Perspective for Bioburden Testing by
Type - Percentage Breakdown of Value Sales for Aerobic,
Anaerobic, Fungi and Spore for the Years 2012, 2018 & 2027

Table 82: China Current & Future Analysis for Bioburden Testing
by Application - Raw Material and In-process - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 83: China Historic Review for Bioburden Testing by
Application - Raw Material and In-process Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 84: China 15-Year Perspective for Bioburden Testing by
Application - Percentage Breakdown of Value Sales for Raw
Material and In-process for the Years 2012, 2018 & 2027

Table 85: China Current & Future Analysis for Bioburden Testing
by End-Use - Pharmaceutical & Biotechnology Companies, Contract
Manufacturing Organizations, Microbial Testing Laboratories and
Other End-Uses - Independent Analysis of Annual Sales in US$
Million for the Years 2018 through 2027

Table 86: China Historic Review for Bioburden Testing by
End-Use - Pharmaceutical & Biotechnology Companies, Contract
Manufacturing Organizations, Microbial Testing Laboratories and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2017

Table 87: China 15-Year Perspective for Bioburden Testing by
End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, Contract
Manufacturing Organizations, Microbial Testing Laboratories and
Other End-Uses for the Years 2012, 2018 & 2027

EUROPE
Market Facts & Figures
European Bioburden Testing Market: Competitor Market Share
Scenario (in %) for 2018 & 2027
Market Analytics
Table 88: Europe Current & Future Analysis for Bioburden
Testing by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2018 through 2027

Table 89: Europe Historic Review for Bioburden Testing by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017

Table 90: Europe 15-Year Perspective for Bioburden Testing by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2018 & 2027

Table 91: Europe Current & Future Analysis for Bioburden
Testing by Product - Instrument and Consumables - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 92: Europe Historic Review for Bioburden Testing by
Product - Instrument and Consumables Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 93: Europe 15-Year Perspective for Bioburden Testing by
Product - Percentage Breakdown of Value Sales for Instrument
and Consumables for the Years 2012, 2018 & 2027

Table 94: Europe Current & Future Analysis for Bioburden
Testing by Type - Aerobic, Anaerobic, Fungi and Spore -
Independent Analysis of Annual Sales in US$ Million for the
Years 2018 through 2027

Table 95: Europe Historic Review for Bioburden Testing by Type -
Aerobic, Anaerobic, Fungi and Spore Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 96: Europe 15-Year Perspective for Bioburden Testing by
Type - Percentage Breakdown of Value Sales for Aerobic,
Anaerobic, Fungi and Spore for the Years 2012, 2018 & 2027

Table 97: Europe Current & Future Analysis for Bioburden
Testing by Application - Raw Material and In-process -
Independent Analysis of Annual Sales in US$ Million for the
Years 2018 through 2027

Table 98: Europe Historic Review for Bioburden Testing by
Application - Raw Material and In-process Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 99: Europe 15-Year Perspective for Bioburden Testing by
Application - Percentage Breakdown of Value Sales for Raw
Material and In-process for the Years 2012, 2018 & 2027

Table 100: Europe Current & Future Analysis for Bioburden
Testing by End-Use - Pharmaceutical & Biotechnology Companies,
Contract Manufacturing Organizations, Microbial Testing
Laboratories and Other End-Uses - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027

Table 101: Europe Historic Review for Bioburden Testing by
End-Use - Pharmaceutical & Biotechnology Companies, Contract
Manufacturing Organizations, Microbial Testing Laboratories and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2017

Table 102: Europe 15-Year Perspective for Bioburden Testing by
End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, Contract
Manufacturing Organizations, Microbial Testing Laboratories and
Other End-Uses for the Years 2012, 2018 & 2027

FRANCE
Table 103: France Current & Future Analysis for Bioburden
Testing by Product - Instrument and Consumables - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 104: France Historic Review for Bioburden Testing by
Product - Instrument and Consumables Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 105: France 15-Year Perspective for Bioburden Testing by
Product - Percentage Breakdown of Value Sales for Instrument
and Consumables for the Years 2012, 2018 & 2027

Table 106: France Current & Future Analysis for Bioburden
Testing by Type - Aerobic, Anaerobic, Fungi and Spore -
Independent Analysis of Annual Sales in US$ Million for the
Years 2018 through 2027

Table 107: France Historic Review for Bioburden Testing by Type -
Aerobic, Anaerobic, Fungi and Spore Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 108: France 15-Year Perspective for Bioburden Testing by
Type - Percentage Breakdown of Value Sales for Aerobic,
Anaerobic, Fungi and Spore for the Years 2012, 2018 & 2027

Table 109: France Current & Future Analysis for Bioburden
Testing by Application - Raw Material and In-process -
Independent Analysis of Annual Sales in US$ Million for the
Years 2018 through 2027

Table 110: France Historic Review for Bioburden Testing by
Application - Raw Material and In-process Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 111: France 15-Year Perspective for Bioburden Testing by
Application - Percentage Breakdown of Value Sales for Raw
Material and In-process for the Years 2012, 2018 & 2027

Table 112: France Current & Future Analysis for Bioburden
Testing by End-Use - Pharmaceutical & Biotechnology Companies,
Contract Manufacturing Organizations, Microbial Testing
Laboratories and Other End-Uses - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027

Table 113: France Historic Review for Bioburden Testing by
End-Use - Pharmaceutical & Biotechnology Companies, Contract
Manufacturing Organizations, Microbial Testing Laboratories and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2017

Table 114: France 15-Year Perspective for Bioburden Testing by
End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, Contract
Manufacturing Organizations, Microbial Testing Laboratories and
Other End-Uses for the Years 2012, 2018 & 2027

GERMANY
Table 115: Germany Current & Future Analysis for Bioburden
Testing by Product - Instrument and Consumables - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 116: Germany Historic Review for Bioburden Testing by
Product - Instrument and Consumables Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 117: Germany 15-Year Perspective for Bioburden Testing by
Product - Percentage Breakdown of Value Sales for Instrument
and Consumables for the Years 2012, 2018 & 2027

Table 118: Germany Current & Future Analysis for Bioburden
Testing by Type - Aerobic, Anaerobic, Fungi and Spore -
Independent Analysis of Annual Sales in US$ Million for the
Years 2018 through 2027

Table 119: Germany Historic Review for Bioburden Testing by
Type - Aerobic, Anaerobic, Fungi and Spore Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017

Table 120: Germany 15-Year Perspective for Bioburden Testing by
Type - Percentage Breakdown of Value Sales for Aerobic,
Anaerobic, Fungi and Spore for the Years 2012, 2018 & 2027

Table 121: Germany Current & Future Analysis for Bioburden
Testing by Application - Raw Material and In-process -
Independent Analysis of Annual Sales in US$ Million for the
Years 2018 through 2027

Table 122: Germany Historic Review for Bioburden Testing by
Application - Raw Material and In-process Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 123: Germany 15-Year Perspective for Bioburden Testing by
Application - Percentage Breakdown of Value Sales for Raw
Material and In-process for the Years 2012, 2018 & 2027

Table 124: Germany Current & Future Analysis for Bioburden
Testing by End-Use - Pharmaceutical & Biotechnology Companies,
Contract Manufacturing Organizations, Microbial Testing
Laboratories and Other End-Uses - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027

Table 125: Germany Historic Review for Bioburden Testing by
End-Use - Pharmaceutical & Biotechnology Companies, Contract
Manufacturing Organizations, Microbial Testing Laboratories and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2017

Table 126: Germany 15-Year Perspective for Bioburden Testing by
End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, Contract
Manufacturing Organizations, Microbial Testing Laboratories and
Other End-Uses for the Years 2012, 2018 & 2027

ITALY
Table 127: Italy Current & Future Analysis for Bioburden
Testing by Product - Instrument and Consumables - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 128: Italy Historic Review for Bioburden Testing by
Product - Instrument and Consumables Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 129: Italy 15-Year Perspective for Bioburden Testing by
Product - Percentage Breakdown of Value Sales for Instrument
and Consumables for the Years 2012, 2018 & 2027

Table 130: Italy Current & Future Analysis for Bioburden
Testing by Type - Aerobic, Anaerobic, Fungi and Spore -
Independent Analysis of Annual Sales in US$ Million for the
Years 2018 through 2027

Table 131: Italy Historic Review for Bioburden Testing by Type -
Aerobic, Anaerobic, Fungi and Spore Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 132: Italy 15-Year Perspective for Bioburden Testing by
Type - Percentage Breakdown of Value Sales for Aerobic,
Anaerobic, Fungi and Spore for the Years 2012, 2018 & 2027

Table 133: Italy Current & Future Analysis for Bioburden
Testing by Application - Raw Material and In-process -
Independent Analysis of Annual Sales in US$ Million for the
Years 2018 through 2027

Table 134: Italy Historic Review for Bioburden Testing by
Application - Raw Material and In-process Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 135: Italy 15-Year Perspective for Bioburden Testing by
Application - Percentage Breakdown of Value Sales for Raw
Material and In-process for the Years 2012, 2018 & 2027

Table 136: Italy Current & Future Analysis for Bioburden
Testing by End-Use - Pharmaceutical & Biotechnology Companies,
Contract Manufacturing Organizations, Microbial Testing
Laboratories and Other End-Uses - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027

Table 137: Italy Historic Review for Bioburden Testing by
End-Use - Pharmaceutical & Biotechnology Companies, Contract
Manufacturing Organizations, Microbial Testing Laboratories and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2017

Table 138: Italy 15-Year Perspective for Bioburden Testing by
End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, Contract
Manufacturing Organizations, Microbial Testing Laboratories and
Other End-Uses for the Years 2012, 2018 & 2027

UNITED KINGDOM
Table 139: UK Current & Future Analysis for Bioburden Testing
by Product - Instrument and Consumables - Independent Analysis
of Annual Sales in US$ Million for the Years 2018 through 2027

Table 140: UK Historic Review for Bioburden Testing by Product -
Instrument and Consumables Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017

Table 141: UK 15-Year Perspective for Bioburden Testing by
Product - Percentage Breakdown of Value Sales for Instrument
and Consumables for the Years 2012, 2018 & 2027

Table 142: UK Current & Future Analysis for Bioburden Testing
by Type - Aerobic, Anaerobic, Fungi and Spore - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 143: UK Historic Review for Bioburden Testing by Type -
Aerobic, Anaerobic, Fungi and Spore Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05956102/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001